Economic TimesLean R·
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70%
EyePoint's experimental drug Duravyu failed a late-stage trial for a serious eye disease. The company's shares dropped significantly after the disappointing trial results were announced. This failure impacts EyePoint's goal to compete with Regeneron's successful Eylea treatment. Analysts suggest investors will await further study confirmation for the drug's viability. EyePoint plans a new trial and FDA submission for approval in 2027.
Read at Economic Times →
